RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.359 – $0.40
Volume42,697
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for RDHL.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for RDHL.
Recent news
Company coverage with links to the original publishers.
The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.
RedHill Biopharma received a Nasdaq Staff Determination letter indicating non-compliance with minimum stockholders' equity requirements. The company plans to appeal the determination and believes its recent transaction with Cumberland Pharmaceuticals has improved its equity position.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday.
The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also rose, gaining, 0.19% to 4,877.88.
Check This Out: How To Earn $500 A Month From Capital One Financial Ahead Of Its Q4 Earnings Report
Leading and Lagging Sectors
Energy shares rose by 1.7% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 1.5%.
Top Headline
American Airlines Group Inc (NASDAQ: AAL) reported better-than-expected fourth-quarter results.
American Airlines reported a 75% drop in adjusted earnings to 29 cents per share in the fourth quarter of 2023 but still came in well above the consensus estimate of 10 cents per share. Total revenue decreased 1% to $13.06 billion, just beating estimates of $13.02 billion.
American Airlines expects its full-year 2024 adjusted earnings per diluted share of $2.25-$3.25 versus the consensus of $2.25.
Equities Trading UP
Vera Therapeutics, Inc. (NASDAQ: VERA) shares shot up 53% to $25.97 after the company announced 72-week data from the OLE period of its Phase 2b ORIGIN clinical trial. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $26 price target.
Shares of Processa ...
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
The company reported a Q4 adjusted loss of 11 cents per share, a turnaround from EPS income of $1.97 per share a year ago, missing the consensus for a loss of 5 cents per share. The insurer reported adjusted revenue of $25.73 billion, compared to $21.30 billion a year ago and the consensus of $25.55 billion.
Humana shares dipped 11.3% to $356.93 on Thursday.
Here are some other stocks moving in today's mid-day session.
Gainers
Onconetix, Inc. (NASDAQ: ONCO) shares surged 137% to $0.3519 after falling over 4% on Wednesday.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) gained 97% to $4.0527 after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine.
Enviva Inc. (NYSE: EVA) climbed 47.4% to $0.5239.
Vera Therapeutics, Inc. (NASDAQ: VERA) shares jumped 46% to $24.84 after the company announced 72-week data from the OLE period of its Phase 2b ORIGIN clinical trial. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $26 price target.
Rail Vision Ltd. (NASDAQ: RVSN) gained 43.8% to $7.78. Foresight's affiliate Rail Vision's Main Line System secured EU Railway Standards approval and certifications.
LAVA Therapeutics N.V. (NASDAQ: LVTX) rose 37.4% to $2.13 after the company announced a clinical trial collaboration and supply agreement with Merck & Co. to evaluate LAVA-1207 in combination with KEYTRUDA.
Acutus Medical, Inc. (NASDAQ: AFIB) shares climbed 30.6% to $0.29. Acutus Medical has been granted European patent number EP3043701 titled "Devices and Methods for Determination of Electrical Dipole Densities on a Cardiac Surface (And Methods for Diagnosing Tissue Health)."
Prairie Operating Co. (NASDAQ: PROP) gained 28.8% to $8.17.
American Superconductor Corporation (NASDAQ: AMSC) shares climbed 28.4% to $12.52 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.
CCSC ...
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday.
The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.
Check This Out: How To Earn $500 A Month From Capital One Financial Ahead Of Its Q4 Earnings Report
Leading and Lagging Sectors
Communication services shares rose by 1.5% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 1.4%.
Top Headline
Tesla, Inc. (NASDAQ: TSLA) shares dipped more than 12% on Thursday after the company reported worse-than-expected fourth-quarter financial results.
Tesla reported fourth-quarter revenue of $25.17 billion, which was up 3% year-over-year. The revenue missed a Street consensus estimate of $25.62 billion, according to data from Benzinga Pro. The company reported earnings per share of 71 cents, which missed a Street consensus estimate of 74 cents per share.
Equities Trading UP
Vera Therapeutics, Inc. (NASDAQ: VERA) shares shot up 40% to $23.87 after the company announced 72-week data from the OLE period of its Phase 2b ORIGIN clinical trial. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $26 price target.
Shares of Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) got a boost, ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.